[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cabaletta Bio Inc (CABA)

Cabaletta Bio Inc (CABA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 309,483
  • Shares Outstanding, K 111,325
  • Annual Sales, $ 0 K
  • Annual Income, $ -167,860 K
  • EBIT $ -172 M
  • EBITDA $ -160 M
  • 60-Month Beta 3.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.46

Options Overview Details

View History
  • Implied Volatility 119.67% (+7.14%)
  • Historical Volatility 66.89%
  • IV Percentile 31%
  • IV Rank 14.84%
  • IV High 362.13% on 09/04/25
  • IV Low 77.42% on 04/02/26
  • Expected Move (DTE 15) 0.51 (17.35%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 317
  • Volume Avg (30-Day) 1,578
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 76,928
  • Open Int (30-Day) 64,162
  • Expected Range 2.43 to 3.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 3
  • High Estimate $-0.38
  • Low Estimate $-0.45
  • Prior Year $-0.71
  • Growth Rate Est. (year over year) +42.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.50 +18.60%
on 03/31/26
3.57 -16.93%
on 04/20/26
+0.49 (+20.04%)
since 03/30/26
3-Month
2.29 +29.48%
on 02/05/26
3.78 -21.56%
on 02/25/26
+0.39 (+15.37%)
since 01/30/26
52-Week
1.11 +167.12%
on 05/08/25
3.78 -21.56%
on 02/25/26
+1.64 (+124.62%)
since 04/30/25

Most Recent Stories

More News
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry  Initial...

CABA : 2.96 (+6.47%)
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically...

CABA : 2.96 (+6.47%)
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, were delivered on time, and have been infused into patients within Cabaletta Bio's RESET™ clinical...

CABA : 2.96 (+6.47%)
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus...

CABA : 2.96 (+6.47%)
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies...

CABA : 2.96 (+6.47%)
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies...

CABA : 2.96 (+6.47%)
Cabaletta Bio Announces 2026 Strategic Priorities

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission – including an outpatient dosing option using a single weight-based dose  IND amendment...

CABA : 2.96 (+6.47%)
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient...

CABA : 2.96 (+6.47%)
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies...

CABA : 2.96 (+6.47%)
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses...

CABA : 2.96 (+6.47%)

Business Summary

Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are...

See More

Key Turning Points

3rd Resistance Point 2.95
2nd Resistance Point 2.90
1st Resistance Point 2.84
Last Price 2.96
1st Support Level 2.72
2nd Support Level 2.67
3rd Support Level 2.61

See More

52-Week High 3.78
Last Price 2.96
Fibonacci 61.8% 2.76
Fibonacci 50% 2.44
Fibonacci 38.2% 2.13
52-Week Low 1.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.